Key Resources


ASGE Guidelines

ASGE evidence-based guidelines provide clinicians with recommendations for the evaluation, diagnosis, and management of patients undergoing endoscopic procedures of the digestive tract. Guidelines are not a substitute for physicians’ opinion on individual patients. Final decision on an intervention should always be based on local expertise and patient preferences.

All recommendations follow a rigorous process based on a systematic review of medical literature as outlined by the National Academy of Medicine (formerly Institute of Medicine) standards for guideline development.

Whenever possible, guidelines are based on the GRADE (Grading of Recommendation Assessment, Development and Evaluation) methodology.

Panels consist of content experts, stakeholders from other specialties, patient representatives, and members of the ASGE Standards of Practice (SOP) Committee.

Each recommendation is based on consideration of the best medical literature, the balance between risks and benefits, cost-effectiveness, patients’ values, and equity.

Panel members provide ongoing conflict of interest (COI) disclosures, including intellectual conflicts of interest, throughout the development and publication of all guidelines in accordance with the ASGE Policy for Managing Declared Conflicts of Interests.

ASGE strives to provide clinically relevant and practical recommendations, which can help standardize patient care and improve outcomes.

If you have any questions or suggestions, please contact Customer Support at Info@asge.org.

The following information is intended only to provide general information and not as a definitive basis for diagnosis or treatment in any particular case. It is very important that you consult your doctor about your specific condition.

Newly Published

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
GRADE Guidelines

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
Upper GI

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
Lower GI

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
Biliary and Pancreatic Endoscopy

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
Adverse Events

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
Privileging and Credentialing

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
GI Endoscopy Unit Operations

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
Screening and Surveillance in Premalignant Conditions

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
Procedural Management in Endoscopy

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
Miscellaneous

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing
Guidelines in Spanish

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing

In Progress Guidelines

ASGE Guideline on the Role of Endoscopy in the Management of Malignant Hilar Obstruction

Early 2021

ASGE Guideline on the Management of Cholangitis

Early 2021

ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility

Estimated 2021

ASGE Guideline on the Role of Endoscopic Submucosal Dissection in the Management of Esophageal and Gastric Mucosal Neoplasia

Estimated 2021

Quality in Endoscopy

Quality documents define the indicators of high-quality endoscopy and how to measure it. ASGE quality indicators are based on a rigorous review process which results in valid metrics for evaluating GI endoscopic procedures. 

Quality in Endoscopy

Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer

Jan 30, 2017, 15:40 PM
The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.
Douglas J. Robertson , Jeffrey K. Lee∗ , C. Richard Boland , Jason A. Dominitz , Francis M. Giardiello , David A. Johnson , Tonya Kaltenbach , David Lieberman , Theodore R. Levin , Douglas K. Rex
Title : Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
Doi org link : http://dx.doi.org/10.1016/j.gie.2016.09.025
Volume : Gastrointest Endosc 2017;85:2-21.e3
URL :
Select a choice : Keep
Content created : Oct 18, 2016, 00:00 AM
File size :
Number :
ExternalPK :
Categories :
  • Colorectal
  • Gastrointestinal Endoscopy Journal
  • Lower GI
  • Practice Guidelines
Tags :
Fecal_immunochemical_testing

Technology Assessments

Technology evaluations provide a review of existing, new, or emerging endoscopic technologies that have an impact on the practice of GI endoscopy. Evaluations are based on a literature review and a search of the MAUDE (U.S. Food and Drug Administration Center for Devices and Radiological Health) database to identify the reported adverse events of a given technology. When financial guidance is indicated, the most recent coding data and list prices at the time of publication are provided.

Technology Assessments
80_logo